Facebook
  •  99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  •  99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease

99% Donepezil Base Pharmaceutical Donepezil CAS 120014-06-4 Treatment of Alzheimer′s Disease

No.FH-M1692
Donepezil Base
CAS Number
: 120014-06-4

Chemical Name: 2,3-Dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one
Molecular Formula: C24H29NO3
Function: Treatment of Alzheimer′s Disease.
$30.50
MOQ:
1kg
Free sample:
Available
  •  99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease
  • 99% Donepezil Base Pharmaceutical Donepezil  CAS 120014-06-4 Treatment of Alzheimer′s Disease

Description

Donepezil Base CAS 120014-06-4 is the second generation of specific reversible central acetylcholinesterase (AChE) inhibitor with little effect on peripheral ache. This product can slow down the decomposition of acetylcholine (ACh) in synaptic space by inhibiting the activity of ache, so as to increase the content of ACh and improve the cognitive function of patients with Alzheimer's disease (AD). The inhibition of acetylcholinesterase activity was 570 times stronger than that of butyrylcholinesterase, and it had high selectivity.

Application
1.
Treatment of Alzheimer's Disease: Donepezil Base CAS 120014-06-4 is primarily used to treat mild to moderate dementia caused by Alzheimer's disease, helping to improve cognitive function and daily living activities.
2. Cognitive Enhancement: It enhances cholinergic neurotransmission by inhibiting the breakdown of acetylcholine, a neurotransmitter essential for memory and learning processes.
3. Symptomatic Relief: By addressing the underlying neurochemical changes in Alzheimer's, Donepezil HCl provides symptomatic relief from memory loss, confusion, and other cognitive impairments.
Function
1. Acetylcholinesterase Inhibition: Donepezil Base CAS 120014-06-4 functions as a reversible inhibitor of acetylcholinesterase, an enzyme responsible for breaking down acetylcholine in the brain.
2. Neurotransmitter Preservation: By inhibiting this enzyme, Donepezil HCl increases the availability of acetylcholine in the synaptic cleft, preserving its activity and enhancing cholinergic neurotransmission.
3. Cognitive Support: This increased acetylcholine levels support cognitive processes such as memory formation, recall, attention, and problem-solving abilities, thereby improving overall cognitive function in patients with Alzheimer's disease.

Download

Message Us